Neuren Pharmaceuticals Management

Management criteria checks 3/4

Neuren Pharmaceuticals' CEO is Jon Pilcher, appointed in May 2020, has a tenure of 3.92 years. total yearly compensation is A$546.34K, comprised of 72.6% salary and 27.4% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth A$7.75M. The average tenure of the management team and the board of directors is 3.8 years and 5.8 years respectively.

Key information

Jon Pilcher

Chief executive officer

AU$546.3k

Total compensation

CEO salary percentage	72.6%
CEO tenure	3.9yrs
CEO ownership	0.3%
Management average tenure	3.8yrs
Board average tenure	5.8yrs

Recent management updates

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

Recent updates

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04

CEO Compensation Analysis

How has Jon Pilcher's remuneration changed compared to Neuren Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	AU$157m
Sep 30 2023	n/a	n/a	AU$106m
Jun 30 2023	n/a	n/a	AU$55m
Mar 31 2023	n/a	n/a	AU$28m
Dec 31 2022	AU$546k	AU$396k	AU$184k
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	n/a	n/a	-AU$7m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	AU$432k	AU$203k	-AU$8m

Compensation vs Market: Jon's total compensation ($USD350.40K) is below average for companies of similar size in the Australian market ($USD1.46M).

Compensation vs Earnings: Jon's compensation has increased by more than 20% in the past year.

CEO

Jon Pilcher

3.9yrs

Tenure

AU$546,338

Compensation

Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jonathan Pilcher	CEO, MD & Executive Director	3.9yrs	AU$546.34k	0.31% A$ 7.7m
Lauren Frazer	CFO & Company Secretary	3.7yrs	no data	no data
Lawrence Glass	Chief Science Officer	20.3yrs	no data	no data
Gerry Zhao	Vice President of Corporate Development	no data	no data	no data
Liza Squires	Chief Medical Officer	1.8yrs	no data	no data

3.8yrs

Average Tenure

Experienced Management: NEU's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jonathan Pilcher	CEO, MD & Executive Director	2.8yrs	AU$546.34k	0.31% A$ 7.7m
Dianne Angus	Independent Non-Executive Director	5.8yrs	AU$75.00k	0.023% A$ 583.4k
Trevor Scott	Independent Non-Executive Director	22.1yrs	AU$75.00k	1.89% A$ 47.0m
Jenny Harry	Independent Non-Executive Director	5.8yrs	AU$75.00k	0.023% A$ 577.0k
Patrick Donald Davies	Independent Non-Executive Chairman	5.8yrs	AU$125.00k	0.21% A$ 5.1m
Joe Basile	Independent Non-Executive Director	1.1yrs	no data	0.0078% A$ 194.5k

5.8yrs

Average Tenure

Experienced Board: NEU's board of directors are considered experienced (5.8 years average tenure).

Neuren Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Independent Non-Executive Director recently bought AU$59k worth of stock

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Recent updates

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Price target increased by 27% to AU$24.22

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Price target increased by 18% to AU$19.14

Now 20% undervalued after recent price drop

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Now 25% undervalued after recent price drop

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Consensus EPS estimates fall by 12%

Price target increased by 8.3% to AU$15.07

Independent Non-Executive Director recently sold AU$15m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 18% to AU$10.60

Consensus EPS estimates fall by 14%

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Price target increased by 12% to AU$8.99

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Price target increased to AU$7.83

Price target increased to AU$7.83

Price target increased to AU$7.37

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Consensus estimates of losses per share improve by 47%

Price target increased to AU$6.62

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Consensus forecasts updated

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Independent Non-Executive Chairman recently bought AU$50k worth of stock

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

New 90-day high: AU$1.49

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

New 90-day high: AU$1.42

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

New 90-day high: AU$1.35

New 90-day low: AU$1.06

New 90-day low: AU$1.15

Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 Trials